Wuhan YZY Biopharma Co., Ltd. (YZYBIO-B) has applied for additional time to distribute its shareholder circular covering three key items:

1) a connected transaction involving the proposed issuance of new domestic shares under a specific mandate, 2) an application for a Whitewash Waiver under the Hong Kong Takeovers Code, and 3) amendments to the company’s Articles of Association.

According to the original schedule, the circular was required to be dispatched within either 15 business days of the 9 September 2026 announcement in line with Listing Rule 14A.68, or within 21 days under Rule 8.2 of the Takeovers Code, whichever was earlier. The company now anticipates it cannot meet the initial deadline of around 30 September 2026 because additional time is needed to finalize information for inclusion.

YZYBIO-B has therefore sought consent from the Securities and Futures Commission’s Executive for an extension until 30 October 2026. The Executive has indicated it is “minded to grant” the request.

The pending circular will contain detailed information on the share subscription, recommendations from two Independent Board Committees, advice from an independent financial adviser, and the notice of the forthcoming extraordinary general meeting.

The board reiterates that there is no assurance the share subscription will proceed and advises shareholders and potential investors to exercise caution when dealing in the company’s securities. The company will issue further announcements as developments occur.

The statement is authorized by Chairman, Executive Director and CEO Dr. Zhou Pengfei on behalf of the board dated 30 September 2026.